Bright Minds stock plunges as FDA halts epilepsy trial

More in Health

• STAT+: The health care affordability midterms, and billing urgent care as ER

  Millions of Americans heading to the polls are letting persistent medical expenses dictate their electoral decisions. The midterm cycle functions as an explicit referendum on the financial strains experienced by workers receiving employer-sponsored health insurance coverage. Contested industry practices, such as classifying urgent care treatments as more expensive emergency room visits, further aggravate these ongoing pocketbook frustrations.

  1 min read
• STAT+: Psilocybin’s lasting benefits prove elusive in mice

  Regulatory milestones and global fertility practices are taking center stage alongside preclinical neuropharmacology updates. Federal health officials have begun evaluating a novel genetic candidate for a debilitating neurological disorder, while investigative findings highlight questionable overseas reproductive therapies aimed at aging patients. Meanwhile, laboratory researchers continue to face scientific hurdles in demonstrating sustained therapeutic efficacy for psychedelic substances.

  1 min read
• Tenerife match abandoned after player collapses

  Spanish second-tier forward Jesus de Miguel was rushed to the hospital after taking a direct knee to the chest during a stoppage-time collision. Emergency responders successfully resuscitated the striker following a cardiac arrest inside the ambulance, leaving the athlete unconscious but in stable condition. The late-game medical crisis deeply distressed players and halted the fixture in its final minutes.

  1 min read